NCT07521254 Noninvasive Technique and High Flow Nasal Oxygen in Respiratory Failure
| NCT ID | NCT07521254 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Minia University |
| Condition | Respiratory Failure |
| Study Type | INTERVENTIONAL |
| Enrollment | 75 participants |
| Start Date | 2025-06-01 |
| Primary Completion | 2026-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 75 participants in total. It began in 2025-06-01 with a primary completion date of 2026-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
After obtaining Institutional Ethical Committee approval of Faculty of Medicine, Minia University and written informed consent from patients or first- degree relatives, this prospective randomized non-blind comparative study will be conducted in adult intensive care unit (ICU) of Anesthesia, Intensive Care and Pain management department Minia university hospital over a period from September 2025 to April 2026. This study is designed to compare the effectiveness of two protocols of sequential use of High Flow Nasal Cannula (HFNC) and noninvasive ventilation (NIV) versus NIV alone in patients with Acute Respiratory failure (ARF) admitted to the intensive care unit (ICU). The study will include 75 patients of both sexes, classified as ASA class Ⅰ-ⅠⅠⅠ, divided into three groups with 25 patients in each group.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 year of both sexes. • Diagnosed with Acute Respiratory Failure (ARF) defined as the combination of a PaO2/FiO2 ratio \< 300 after 15 minutes of conventional oxygen delivered through a face mask, with a FiO2 at least of 50% and respiratory rate \> 30 breaths/min. Exclusion Criteria: * Chronic respiratory disease * Cardiogenic pulmonary edema * Life-threatening arrythmias * Hemodynamic instability requiring vasopressors * Facial abnormalities preventing NIV or HFNC application * Glasgow coma score of ≤ 12 points (Teasdale et al. 1974) * Agitated patients characterized by RASS score (Richmond Agitation Sedation Scale) ≥ +2 * Patients who needed immediate endotracheal intubation * Pregnant patients
Contact & Investigator
Omyma S Mohamed, Prof.
PRINCIPAL INVESTIGATOR
ahmed_ezz@mu.edu.eg
Frequently Asked Questions
Who can join the NCT07521254 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Respiratory Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07521254 currently recruiting?
Yes, NCT07521254 is actively recruiting participants. Contact the research team at Omaima.Shehata@mu.edu.eg for enrollment information.
Where is the NCT07521254 trial being conducted?
This trial is being conducted at Minya, Egypt.
Who is sponsoring the NCT07521254 clinical trial?
NCT07521254 is sponsored by Minia University. The principal investigator is Omyma S Mohamed, Prof. at ahmed_ezz@mu.edu.eg. The trial plans to enroll 75 participants.